Galecto Inc. (NASDAQ: GLTO) Leading the Way in Tuesday Trading Based on Percentage GainGalecto, Inc. (
NASDAQGLTO) is one of today’s top gainers. The company’s shares are currently up 21.12% on the day to $2.81.
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (
NASDAQGLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter and year ended December 31, 2022.
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare ConferenceBOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (
NASDAQGLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present and be available for 1x1 meetings at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually on March 13-15, 2023. Details for the event are as follows:
Galecto to Participate in SVB Securities Global Biopharma ConferenceBOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (
NASDAQGLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming SVB Securities Global Biopharma Conference taking place on February 14-16, 2023. Details for the event are as follows:
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual MeetingIntermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients
Galecto Reports Third Quarter Operating and Financial ResultsBOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (
NASDAQGLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended September 30, 2022.
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis PatientsBOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (
NASDAQGLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virtual webinar today, Tuesday, November 8th at 8:00 a.m. ET. The study was selected for a late-breaking oral presentation at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2022.
Galecto to Participate in Jefferies London Healthcare ConferenceBOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (
NASDAQGLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming Jefferies London Healthcare Conference taking place on November 15-17, 2022. Details for the event are as follows:
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (
NASDAQGLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. GULLIVER-2 is a clinical trial designed to assess GB1211, an orally available and high-affinity small molecule carbohydrate-based galectin-3 inhibitor, for the treatment of severe liver diseases. Galectin-3 is a pro-fibrotic β-galactoside binding protein highly expressed in fibrotic livers and implicated in severe liver diseases.
